Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005:103:76-81; discussion 81-3.

Intravitreal clearance of moxifloxacin

Mohan N Iyer  1 , Feng He, Theodore G Wensel, William F Mieler, Matthew S Benz, Eric R Holz
Affiliations

Intravitreal clearance of moxifloxacin

Mohan N Iyer et al. Trans Am Ophthalmol Soc. 2005.

Abstract

Purpose: To study the clearance of a single dose of intravitreally injected moxifloxacin in rabbits.

Methods: Intravitreal injections of 200 microg/0.1 mL of moxifloxacin were performed in rabbits. Four eyes per time interval after injection (1, 6, 12, 24, 36 hours) and three eyes at 48 hours were enucleated, immediately frozen, and placed at -80 degrees C. Ocular dissection and isolation of frozen vitreous were performed. Antibiotic assays were performed with use of high-performance liquid chromatography.

Results: The concentration of intravitreal moxifloxacin showed an exponential decay with a half-life of 1.72 hours. The mean vitreous concentration was 120.49 +/- 49.23 microg/mL 1 hour after injection, which declined to 20.23 +/- 5.85 microg/mL at 6 hours and 1.06 +/- 0.81 microg/mL at 12 hours. The aqueous levels of moxifloxacin showed an exponential decay from 10 microg/mL at 1 hour after intravitreal injection to undetectable levels by 12 hours after injection.

Conclusions: Moxifloxacin clearance from the vitreous is rapid and consistent with previous clearance studies of ciprofloxacin. Given that the injected dose corresponds to several times the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC90) of organisms commonly involved in endophthalmitis, and that therapeutic levels are present up to 12 hours after injection, intravitreal moxifloxacin may have a role in the treatment of endophthalmitis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Moxifloxacin concentrations in the vitreous following intravitreal injection of 200 μg/0.1 mL of moxifloxacin.
FIGURE 2
FIGURE 2
Moxifloxacin concentrations in the aqueous following intravitreal injection of 200 μg/0.1 mL moxifloxacin.
See this image and copyright information in PMC

References

    1. Endophthalmitis Vitrectomy Study Group. . Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravitreous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–1496. - PubMed
    1. Aaberg TM, Flynn HW, Jr, Murray TG. Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Arch Ophthalmol. 1994;112:18–19. - PubMed
    1. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1–17. - PubMed
    1. Benz MS, Scott IU, Flynn HW, Jr, et al. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137:38–42. - PubMed
    1. Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol. 1999;128:240–242. - PubMed

Publication types

MeSH terms